Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Impedimed Limited ( (AU:IPD) ) has provided an update.
ImpediMed Limited has announced the release of its Appendix 4C Quarterly Cash Flow Report for the period ending 30 June 2025, scheduled for 31 July 2025. The company will host an investor conference call on the same day, led by CEO Dr. Parmjot Bains and CF&OO McGregor Grant, to discuss the results and address investor inquiries. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on the development and distribution of bioimpedance spectroscopy devices. These devices are primarily used for the non-invasive assessment of lymphedema and body composition, serving healthcare providers and patients globally.
Average Trading Volume: 2,400,105
Technical Sentiment Signal: Sell
Current Market Cap: A$77.04M
Learn more about IPD stock on TipRanks’ Stock Analysis page.